This project is about producing meat with the technology of bioorganic printing. …mehr lesen »
3D bioprinting is already being used in a number of bioprinting …mehr lesen »
The printer looks like a toaster oven with the front and sides removed. Its metal frame is built up around a stainless steel circle lit by an ultraviolet light.
…mehr lesen »
One of the biggest shortcomings of 3D printing is the enormous amount of waste we produce. If you’re a regular ABS user, you must also be acquainted with the garbage bags full of non-biodegradable failed prints that are accumulating around you.
…mehr lesen »
U.S. biotech startup BioBots sits at the intersection between computer science and chemistry.
…mehr lesen »
Once upon a time, the concept of 3D printing organs was only in the imaginations of mad science fiction writers. Today, breakthroughs in 3D organ printing, also called bioprinting, are moving along at a faster clip than humans might ever have imagined.
(…weiter auf lpfrg.com)
3D-Druck von Hautzellen – Das visionäre Projekt „Vivio“ ist eine medizinische Produktkonzeption, die sich mit der Behandlung von Erkrankungen und Beschädigungen der Haut beschäftigt.
In der letzten Zeit wurde das Thema Haut- und Organdruck immer mehr publik. Da ich dieses Themengebiet sehr interessant fand, habe ich mich intensiver damit beschäftigt. Dabei konnte ich feststellen, dass bis jetzt kein Designkonzept dafür existiert, um diese innovative Technologie verständlich für Ärzte, potentielle Patienten und alle Interessierten darzustellen.
(…weiter auf jamesdysonaward.org)
This was may day so far: I wrote about an amazing new development in the adoption of 3D printing for surgery in Italy, an incredible new 3D printing technology developed by a graduate student in Buffalo, and a stunning “smart doll” created by a self-described gaijin (non-Japanese person) in Japan. Only a couple of years ago, this would be science fiction. Instead, to top it off, here I am enjoying the sunset with a Campari Spritz, writing about my interview with Vladimir Mironov, the scientist behind most of the work at Russia’s 3D Bioprinting Solutions (3D Bio for short).
(…weiter auf 3dprintingindustry.com)
SAN DIEGO, April 1, 2015 /PRNewswire/ — Organovo Holdings, Inc. (NYSE MKT: ONVO) („Organovo“), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, presented data on the company’s in vitro three-dimensional kidney tissue at the 2015 Experimental Biology conference in Boston, Massachusetts.
„Kidney represents an ideal extension of Organovo’s capabilities to 3D bioprint organ tissues that can be tremendously useful in pharmaceutical research,“ said Keith Murphy, Chairman and Chief Executive Officer at Organovo. „The results released today admirably demonstrate a proof of concept that kidney is on the way to becoming another core commercial tissue for Organovo. The product that we intend to build from these initial results can be an excellent expansion for our core customers in toxicology, who regularly express to us an interest in having better solutions for the assessment of human kidney toxicity.“
For the first time, fully human kidney proximal tubular tissues have been generated that are three-dimensional, and consist of multiple tissue-relevant cell types arranged to recapitulate the renal tubular / interstitial interface. The tissues are fabricated using Organovo’s proprietary NovoGenTM bioprinting platform, and will ultimately join the company’s exVive3DTM Liver tissues to expand the repertoire of physiologically-relevant tissue systems available for toxicity and efficacy testing as well as disease modeling. Dr. Sharon Presnell, Chief Technology Officer and Executive Vice President of Research and Development, stated, „Our bioprinted human kidney tissue represents a significant technical advance over the simple monolayer cell line cultures that predominate today. The histologic and functional features of the initial prototypes are compelling, and the in vitro durability of the system will likely enable the assessment of drug effects at chronic, physiologically relevant doses. Furthermore, the cellular complexity of the system will likely support mechanistic investigations into drug responses, including end points that have been difficult or impossible to assess in vitro, including tubular fibrosis and post-injury recovery.“
Key findings and attributes from Organovo’s research include:
(…weiter auf organovo.com)